# AMED Ventures

> AMED Ventures is a VC fund in San Francisco backing Health Care and Medical Device. See 22 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 22
- Last investment: Jun 2026
- Lead investor: 5%
- Last updated: Aug 2026

AMED Ventures is a VC fund in San Francisco focused on Health Care and Medical Device. AMED Ventures

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 50% |
| Medical Device | 9 | 41% |
| Medical | 8 | 36% |
| Biotechnology | 5 | 23% |
| Training | 1 | 5% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 27% |
| Series C | 5 | 23% |
| Venture - Series Unknown | 4 | 18% |
| Series E | 3 | 14% |
| Series A | 2 | 9% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rejoni | Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $25M | Venture - Series Unknown | Jun 16, 2026 |  |
| Kandu Health | Kandu Health is a tech-enabled healthcare company that provides stroke recovery training, stroke detection research, and education services. | $30M | Venture - Series Unknown | Apr 08, 2025 |  |
| Supira Medical | Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $120M | Series E | Mar 26, 2025 |  |
| Imperative Care | Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $150M | Series E | Jul 25, 2024 |  |
| Adona Medical | Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options andenable providers to improve care for heart failure patients. | $33.5M | Series C | Jul 10, 2024 |  |
| Supira Medical | Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $40M | Series D | Nov 21, 2023 |  |
| Akura Medical | Akura Medical offers products and services centered on mechanical thrombectomy and imaging software for venous thromboembolism treatment. Its Katana Thrombectomy System uses a steerable catheter with integrated jet-based technology to access clot material, break it down, and support clot removal during a procedure. The system provides proceduralfeedback intended to help clinicians assess clot engagement and clearance while operating the device. Akura Medical also develops NavIQ, a software tool that transforms CT angiograms into 3D vascular models that display clot location and morphology to guide procedural planning. Together, these products form a workflow that supports physicians from pre-procedure assessment through clot extraction in cases involving pulmonary embolism and related VTE conditions. | $35M | Series B | Oct 03, 2023 |  |
| Instylla | Instylla’s focus is to leverage hydrogel technology . | $30M | Series C | Aug 15, 2023 |  |
| Sealonix | Sealonix focuses on the development and commercialization of hemostatic sealants using its proprietary biomaterials. Sealonix is working on a sealant patch that will provide quick hemostasis for abdominopelvic and orthopedic operations. The PramStat patch is intended to bioabsorb within one week of implantation. | $20M | Series A | May 12, 2023 |  |
| Tioga Cardiovascular | Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach. | $30M | Series C | Feb 09, 2023 |  |

10 of 22 investments shown.

## Co-investors
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 11 deals together
- [The Capital Partnership](https://shizune.co/investors/profile/the-capital-partnership) — VC Fund, 9 deals together
- [Excelestar Ventures](https://shizune.co/investors/profile/excelestar-ventures) — VC Fund, 6 deals together
- [Shifamed](https://shizune.co/investors/profile/shifamed) — VC Fund, 6 deals together
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 5 deals together
- [Sparta Group](https://shizune.co/investors/profile/sparta-group-llc) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does AMED Ventures invest in?

AMED Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did AMED Ventures last invest?

The most recent investment recorded for AMED Ventures closed in Jun 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co